HYPofractionated Adjuvant RadioTherapy in 1 versus 2 weeks in high-risk patients with breast cancer (HYPART): a non-inferiority, open-label, phase III randomised trial.
Journal Information
Full Title: Trials
Abbreviation: Trials
Country: Unknown
Publisher: Unknown
Language: N/A
Publication Details
Related Papers from Same Journal
Transparency Score
Transparency Indicators
Click on green indicators to view evidence textCore Indicators
"Declarations Ethics approval and consent to participateThe trial was approved by Institute Ethics Committee wide No. PGI/IEC/2021/000453 dated 30 March 2021. If there is any deviation in the protocol or modification prior, IEC approval will be taken. Consent for publicationNot applicable. Competing interestsThe authors declare no competing interests. Competing interests The authors declare no competing interests."
"Funding Indian Council of Medical Research V. Ramalingaswami Bhawan, P.O. Box No. 4911 Ansari Nagar, New Delhi, 110029, India Ph: 91-11-26588895/91-11-26588980, 91-11-26589794/91-11-26589336, 91-11-26588707 Fax: 91-11-26588662 Email: icmrhqds@sansad.nic.in"
"Trial registration The trial is registered with ClinicalTrials.gov ID NCT04472845 and CTRI with REF/2020/09/037050."
Additional Indicators
Assessment Info
Tool: rtransparent
OST Version: N/A
Last Updated: Aug 05, 2025